This Activity is no longer available for CME credit.

Release Date: July 26, 2006
Valid Through: July 25, 2007

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM

Fee: There is no fee for this activity

This CME activity is based on the following original interactive case study:

Biomarkers and Adjuvant Treatment Planning Strategies for Patients with a Node-Negative, Estrogen Receptor-Positive Breast Cancer
David M. Hyams, MD, FACS and Ruth Oratz, MD, FACP

Dr. Hyams brings 20 years of experience to his practice of General Surgical Oncology. He is board certified and specializes in the management of breast, endocrine, soft tissue, and gastrointestinal tumors. Additionally, he serves as National Director of Clinical Research for Aptium Oncology. Dr. Hyams has held full-time faculty appointments at two university medical centers, and he is an invited lecturer worldwide. He joined the Comprehensive Cancer Center in 1999 after having served as executive medical officer and director of medical affairs for the National Surgical Adjuvant Breast and Bowel Project. He earned his medical degree from Columbia University and completed surgical oncology training at the National Cancer Institute and the City of Hope National Medical Center.

Ruth Oratz, MD, FACP

Dr. Oratz is Associate Professor of Clinical Medicine at New York University School of Medicine. A Fellow of the American College of Physicians, Dr. Oratz graduated from Radcliffe College/Harvard University and the Albert Einstein College of Medicine. She then completed her post-doctoral training in internal medicine and medical oncology at the New York University School of Medicine in New York, New York. Dr. Oratz has been active in clinical research and is widely published in her field.

Dr. Oratz is a board certified medical oncologist and has been in practice since 1988. She specializes in treating women with breast cancer and other malignancies and those at high risk for cancer. Dr. Oratz is especially committed to helping women with cancer continue to live active and full lives, placing significant attention on flexible treatment programs and those that address women's concerns about career, family life, relationships, and sexuality. Dr. Oratz was named “Physician of the Year” by CancerCare® in 2005 and has been listed in “The Best Doctors in America” in Redbook Magazine and “The Best Doctors in NYC” in New York Magazine.

As a speaker, Dr. Oratz is active both locally and nationally, appearing on television and radio as well as lecturing to the public. She is an advisor to several national organizations, including BreastCancer.org, Living Beyond Breast Cancer, Cancer and Careers, Young Survival Coalition, and Sharsheret: Linking Young Jewish Women in Their Fight Against Breast Cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Understand the benefits of performing a breast cancer assay for optimal treatment planning during breast cancer staging and workup.
• Evaluate the published clinical data for the evolving role of biomarkers in the diagnosis, prognosis, and treatment of Stage I or II, node-negative, hormone receptor-positive breast cancers that will be treated with tamoxifen.
• Recognize the relevance, validity, and reproducibility of breast cancer assays for node-negative, estrogen receptor-positive breast cancers.
• Identify the clinical impact of adjuvant chemotherapy on early stage breast cancer patients with a low, intermediate, or high risk for recurrence.

Disclaimer
Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters
This activity is supported by an unrestricted educational grant from Genomic Health, Inc.